Syndax Pharmaceuticals Inc (SNDX) Stock
5 of the hedge funds AlphaScala tracks reported SNDX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $44.90M.
Which hedge funds own SNDX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 2.05M | $44.90M | +929% |
| D.E. Shaw David Shaw | 1.24M | $27.11M | -23% |
| Renaissance Technologies Jim Simons (founder) | 322K | $7.03M | -35% |
| Citadel Ken Griffin | 258K | $5.65M | -59% |
| Hussman Investment Trust John Hussman | 84K | $1.84M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →SNDX price chart
Powered by TradingViewWhat does Syndax Pharmaceuticals Inc do?
Syndax Pharmaceuticals Inc. is a commercial stage oncology innovator focused on developing cancer therapies for areas of significant unmet medical need. The company's product portfolio includes Revuforj, a menin inhibitor approved for treating relapsed or refractory NPM1-mutated acute myeloid leukemia in adult and pediatric patients, along with Niktimvo, an axatilimab-based therapeutic. The company also operates proprietary platforms including SyndAccess and IncyteCARES, which support its drug development and patient care initiatives. Syndax Pharmaceuticals targets oncologists and patients dealing with acute leukemias and related hematologic malignancies, positioning itself within the biotechnology sector as a specialized pharmaceutical developer addressing critical gaps in cancer treatment. Founded in 2005 and headquartered in New York, the company combines research-stage development capabilities with commercial product distribution to serve the global oncology market.